Italy Opens Competition Probe Into Biogen Over Multiple Sclerosis Drug Practices
Italy’s competition watchdog said this week it has opened a probe into Biogen and its Italian subsidiary over allegations the company used control of a critical screening test to box out a lower-cost rival in the market for multiple sclerosis drugs containing natalizumab. The accusation is technical. The implications are not.
